# Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)

> **NCT00972816** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 1357 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** MF59-eH1N1

## Key facts

- **NCT ID:** NCT00972816
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-11
- **Final completion:** 2010-10
- **Target enrollment:** 1357 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00972816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00972816, "Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00972816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*